Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Cattaneo, F. Antoniazzi, Salvatore Casari, G. Ravizzola, M. Gelmi, C. Pagani, M. D’adda, Enrico Morello, Alessandro Re, E. Borlenghi, N. Manca, Giorgio Rossi (2012)
P. aeruginosa bloodstream infections among hematological patients: an old or new question?Annals of Hematology, 91
A. Xiao, B. Miller, Jennifer Huntington, D. Nicolau (2015)
Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic‐derived dose justification for phase 3 studies in patients with nosocomial pneumoniaJournal of Clinical Pharmacology, 56
M. Mikulska, V. Bono, Paolo Bruzzi, A. Raiola, F. Gualandi, M. Lint, A. Bacigalupo, Claudio Viscoli (2012)
Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipientsInfection, 40
M. Mikulska, V. Bono, A. Raiola, B. Bruno, F. Gualandi, D. Occhini, C. Grazia, F. Frassoni, A. Bacigalupo, C. Viscoli (2009)
Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 15 1
F. Fitzgerald, K. Wing, A. Naveed, M. Gbessay, J. Ross, F. Checchi, D. Youkee, M. Jalloh, D. Baion, A. Mustapha, H. Jah, S. Lako, S. Oza, S. Boufkhed, R. Feury, J. Bielicki, E. Williamson, D. Gibb, N. Klein, F. Sahr, S. Yeung (2017)
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of ResistanceClinical Infectious Diseases, 65
M. Pfaller, M. Bassetti, Leonard Duncan, M. Castanheira (2017)
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15)Journal of Antimicrobial Chemotherapy, 72
A. Magiorakos, A. Srinivasan, R. Carey, Y. Carmeli, M. Falagas, M. Falagas, C. Giske, S. Harbarth, J. Hindler, G. Kahlmeter, B. Olsson-liljequist, D. Paterson, L. Rice, J. Stelling, M. Struelens, A. Vatopoulos, J. Weber, D. Monnet (2012)
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 18 3
J. Munita, S. Aitken, William Miller, F. Pérez, R. Rosa, L. Shimose, Paola Lichtenberger, L. Abbo, R. Jain, M. Nigo, A. Wanger, R. Araos, T. Tran, J. Adachi, R. Rakita, S. Shelburne, R. Bonomo, C. Arias (2017)
Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosaClinical Infectious Diseases, 65
J. Castón, A. Torre, I. Ruiz-Camps, M. Sorlí, Vicente Torres, J. Torre-Cisneros (2016)
Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa InfectionsAntimicrobial Agents and Chemotherapy, 61
E. Trecarichi, M. Tumbarello, M. Caira, A. Candoni, C. Cattaneo, D. Pastore, R. Fanci, A. Nosari, N. Vianelli, A. Busca, A. Spadea, L. Pagano (2011)
Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignanciesHaematologica, 96
D. Shortridge, M. Castanheira, M. Pfaller, R. Flamm (2017)
Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015Antimicrobial Agents and Chemotherapy, 61
M. Satlin, T. Walsh (2017)
Multidrug‐resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin‐resistant Enterococcus: Three major threats to hematopoietic stem cell transplant recipientsTransplant Infectious Disease, 19
Morgan Hakki, Morgan Hakki, Ajit Limaye, Hyung Kim, Katharine Kirby, Lawrence Corey, Lawrence Corey, M. Boeckh, M. Boeckh (2007)
Invasive Pseudomonas aeruginosa infections: high rate of recurrence and mortality after hematopoietic cell transplantationBone Marrow Transplantation, 39
A. Dinh, B. Wyplosz, S. Kernéis, D. Lebeaux, F. Bouchand, C. Duran, G. Béraud, Pauline Lazaro, B. Davido, S. Hénard, E. Canouï, T. Ferry, M. Wolff (2017)
Use of ceftolozane/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa.International journal of antimicrobial agents, 49 6
H. Sader, D. Farrell, M. Castanheira, R. Flamm, Ronald Jones (2014)
Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).The Journal of antimicrobial chemotherapy, 69 10
E. Trecarichi, M. Tumbarello (2014)
Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impactCurrent Opinion in Infectious Diseases, 27
D. Caselli, S. Cesaro, O. Ziino, G. Zanazzo, R. Manicone, S. Livadiotti, M. Cellini, S. Frenos, G. Milano, B. Cappelli, M. Licciardello, C. Beretta, M. Aricò, E. Castagnola (2010)
Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantationHaematologica, 95
Shawn MacVane, R. Pandey, L. Steed, B. Kreiswirth, Liang Chen (2017)
Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural MutationAntimicrobial Agents and Chemotherapy, 61
S. Aitken, D. Kontoyiannis, April DePombo, Micah Bhatti, Frank Tverdek, Suzanne Gettys, D. Nicolau, C. Nunez (2016)
Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant Pseudomonas aeruginosa Bloodstream Infection in a Pediatric Leukemia Patient.Pediatric Infectious Disease Journal
Multidrug-resistant (MDR) Pseudomonas aeruginosa infection causes significant mortality among patients with hematologic malignancies and hematopoietic-cell transplant recipients. Ceftolozane-tazobactam (C-T) is a novel therapeutic option for MDR-P. aeruginosa infections but clinical experience in these patients is limited. We report favorable clinical outcomes and lack of limiting toxicities using C-T monotherapy to treat invasive MDR-P. aeruginosa infections in these patient populations.
Infection – Springer Journals
Published: Feb 19, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.